{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:34:30Z","timestamp":1780569270783,"version":"3.54.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Chronic recalcitrant erythema nodosum leprosum (ENL) or type 2 reaction (T2R) is a severe condition found in approximately 50% of multibacillary leprosy subjects. T2R is associated with important morbidities and may lead to several disabilities, not only due to nerve damage but also due to the prolonged use of corticosteroids, thalidomide, or immunosuppressors. We describe here four leprosy patients with chronic recalcitrant ENL treated with cyclophosphamide pulse therapy. All subjects had been on prednisone and thalidomide therapy for at least 30\u2009months but showed inflammatory activity when doses were reduced. Pulse therapy with 1.0\u2009g of cyclophosphamide was used every 4\u20136\u2009weeks for a minimum of three applications. After pulse therapy, all cases presented total or partial regression of symptoms, and we were able to taper thalidomide and prednisone doses, with better control of ENL, avoiding further hospital admissions and disabilities. No side effects were observed during or after infusion therapy. Cyclophosphamide pulse therapy may be useful and safe to control chronic recalcitrant ENL.<\/jats:p>","DOI":"10.3389\/fmed.2023.1272404","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T10:29:15Z","timestamp":1698229755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum"],"prefix":"10.3389","volume":"10","author":[{"given":"Gustavo U.","family":"Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Amparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via","family":"Bulh\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo R. L.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.actatropica.2018.02.026","article-title":"Erythema Nodosum Leprosum: update and challenges on the treatment of a neglected condition","volume":"183","author":"Costa","year":"2018","journal-title":"Acta Trop"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e2690","DOI":"10.1371\/journal.pntd.0002690","article-title":"The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study","volume":"8","author":"Walker","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMc052955","article-title":"Treatment of recurrent erythema nodosum leprosum with infliximab","volume":"355","author":"Faber","year":"2006","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4269\/ajtmh.19-0616","article-title":"Biologics in leprosy: a systematic review and case report","volume":"102","author":"Cogen","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1111\/jdv.17585","article-title":"Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single-centre pilot study","volume":"35","author":"Narang","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ajd.12406","article-title":"Cyclophosphamide in dermatology","volume":"58","author":"Kim","year":"2016","journal-title":"Australas J Dermatol"},{"key":"ref7","first-page":"255","article-title":"Classification of leprosy according to immunity. A five-group system","volume":"34","author":"Ridley","year":"1966","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e0003865","DOI":"10.1371\/journal.pntd.0003865","article-title":"Viral co-infection and leprosy outcomes: a cohort study","volume":"9","author":"Machado","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0005716","DOI":"10.1371\/journal.pntd.0005716","article-title":"A leprosy clinical severity scale for erythema nodosum leprosum: an international, multicentre validation study of the ENLIST ENL severity scale","volume":"11","author":"Walker","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jpsychores.2014.02.006","article-title":"Mental disorders in leprosy: an underdiagnosed and untreated population","volume":"76","author":"Rocha-Leite","year":"2014","journal-title":"J Psychosom Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/0091217415582173","article-title":"Perception of social exclusion, neuropathy, and quality of life among Hansen's disease patients","volume":"49","author":"Borges-de-Oliveira","year":"2015","journal-title":"Int J Psychiatry Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e0010761","DOI":"10.1371\/journal.pntd.0010761","article-title":"Experiences of living with leprosy: a systematic review and qualitative evidence synthesis","volume":"16","author":"Abdul Rahman","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"ref13","volume-title":"Leprosy","year":"2023"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"CD006949","DOI":"10.1002\/14651858.CD006949.pub2","article-title":"Interventions for erythema nodosum leprosum","volume":"8","author":"Van Veen","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.4049\/jimmunol.149.4.1470","article-title":"Cytokine patterns of immunologically mediated tissue damage","volume":"149","author":"Yamamura","year":"1992","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fimmu.2017.00233","article-title":"A systematic review of immunological studies of erythema nodosum leprosum","volume":"8","author":"Polycarpou","year":"2017","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.micinf.2018.10.003","article-title":"Evaluation of monocyte subsets and markers of activation in leprosy reactions","volume":"21","author":"Shibuya","year":"2019","journal-title":"Microbes Infect"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"879527","DOI":"10.3389\/fmed.2022.879527","article-title":"Case report: A case series of immunobiological therapy (anti-TNF-\u03b1) for patients with erythema Nodosum Leprosum","volume":"9","author":"Mendes","year":"2022","journal-title":"Front Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1590\/abd1806-4841.20131840","article-title":"Pulse therapy in pemphigus: report of 11 cases","volume":"88","author":"Fernandes","year":"2013","journal-title":"An Bras Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archderm.135.1.57","article-title":"Pulse intravenous cyclophosphamide therapy in pemphigus","volume":"135","author":"Fleischli","year":"1999","journal-title":"Arch Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/8345737","article-title":"Revisited cyclophosphamide in the treatment of lupus nephritis","volume":"2022","author":"Quan","year":"2022","journal-title":"Biomed Res Int"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1272404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:49:51Z","timestamp":1698752991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1272404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":23,"alternative-id":["10.3389\/fmed.2023.1272404"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1272404","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"article-number":"1272404"}}